License to kill: Formulation requirements for optimal priming of CD8 + CTL responses with particulate vaccine delivery systems

European Journal of Pharmaceutical Sciences

Volumn 45, Issue 4, 2012, Pages 482-491

  Foged, Camilla ^a   Hansen, Jon ^b   Agger, Else Marie ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b STATENS SERUM INSTITUT   (Denmark)

Author keywords

Adjuvant; CD8 + T cells; Cytotoxic T lymphocyte; Particulate vaccine; Subunit vaccine; Vaccination

Indexed keywords

ALPHA TOCOPHEROL; CANCER VACCINE; CHOLESTEROL; CPG OLIGODEOXYNUCLEOTIDE; DIMETHYLDIOCTADECYLAMMONIUM BROMIDE; DIOLEOYLPHOSPHATIDYLCHOLINE; DIPALMITOYLPHOSPHATIDYLCHOLINE; FREUND ADJUVANT; FUSOGENIC LIPOSOME; IMMUNOLOGICAL ADJUVANT; ISCOM; LIPID; LIPOSOME; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONTANIDE ISA 51; NANOPARTICLE; OLIGODEOXYNUCLEOTIDE; OVALBUMIN; PHOSPHORYL LIPID A; POLYGLACTIN; POLYINOSINIC POLYCYTIDYLIC ACID; POLYMER; SAPONIN; SQUALENE; SUBUNIT VACCINE; UNCLASSIFIED DRUG; VACCINE; VIROSOME; VIRUS VACCINE; WATER OIL CREAM;

ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONFERENCE PAPER; CROSS PRESENTATION; CYTOSOL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; HUMAN; NONHUMAN; PARTICLE SIZE; PHAGOSOME; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS; HUMANS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, SUBUNIT;

EID: 83055188992     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2011.08.016     Document Type: Conference Paper

References (134)

1. A.L. Ackerman, C. Kyritsis, R. Tampe, and P. Cresswell Early phagosomes in dendritic cells form a cellular compartment sufficient for cross presentation of exogenous antigens Proc. Natl Acad. Sci. USA 100 2003 12889 12894 (Pubitemid 37339995)
2. M.L. Albert, B. Sauter, and N. Bhardwaj Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs Nature 392 1998 86 89 (Pubitemid 28150594)
3. Y. Ataman-Onal, S. Munier, A. Ganee, C. Terrat, P.Y. Durand, N. Battail, F. Martinon, R. Le Grand, M.H. Charles, T. Delair, and B. Verrier Surfactant-free anionic PLA nanoparticles coated with HIV-1 p24 protein induced enhanced cellular and humoral immune responses in various animal models J. Controlled Release 112 2006 175 185
4. + dendritic cells J. Exp. Med. 207 2010 1273 1281
5. M.F. Bachmann, and G.T. Jennings Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns Nat. Rev. Immunol. 10 2010 787 796
6. J. Banchereau, and R.M. Steinman Dendritic cells and the control of immunity Nature 392 1998 245 252 (Pubitemid 28155090)
7. S. Basta, and A. Alatery The cross-priming pathway: a portrait of an intricate immune system Scand. J. Immunol. 65 2007 311 319 (Pubitemid 46481103)
8. G.T. Belz, G.M. Behrens, C.M. Smith, J.F. Miller, C. Jones, K. Lejon, C.G. Fathman, S.N. Mueller, K. Shortman, F.R. Carbone, and W.R. Heath The CD8alpha(+) dendritic cell is responsible for inducing peripheral self-tolerance to tissue-associated antigens J. Exp. Med. 196 2002 1099 1104 (Pubitemid 35231768)
9. M.J. Bevan Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay J. Exp. Med. 143 1976 1283 1288
10. M.J. Bevan Minor H antigens introduced on H-2 different stimulating cells cross-react at the cytotoxic T cell level during in vivo priming J. Immunol. 117 1976 2233 2238 (Pubitemid 8009022)
11. M.J. Bevan, R.E. Langman, and M. Cohn H-2 antigen-specific cytotoxic T cells induced by concanavalin A: estimation of their relative frequency Eur. J. Immunol. 6 1976 150 156
12. D.E. Bloom, D. Canning, and M. Weston The value of vaccination World Econ. 6 2005 15 39
13. + T cell tolerance J. Exp. Med. 196 2002 1627 1638 (Pubitemid 36026474)
14. P.A. Bovier Recent advances with a virosomal hepatitis A vaccine Expert Opin. Biol. Ther. 8 2008 1177 1185
15. K.E. Broaders, J.A. Cohen, T.T. Beaudette, E.M. Bachelder, and J.M. Frechet Acetalated dextran is a chemically and biologically tunable material for particulate immunotherapy Proc. Natl Acad. Sci. USA 106 2009 5497 5502
16. L. Bungener, K. Serre, L. Bijl, L. Leserman, J. Wilschut, T. Daemen, and P. Machy Virosome-mediated delivery of protein antigens to dendritic cells Vaccine 20 2002 2287 2295 (Pubitemid 34497039)
17. S. Burgdorf, and C. Kurts Endocytosis mechanisms and the cell biology of antigen presentation Curr. Opin. Immunol. 20 2008 89 95
18. M.S. Campo, and R.B. Roden Papillomavirus prophylactic vaccines: established successes, new approaches J. Virol. 84 2010 1214 1220
19. M. Cella, D. Jarrossay, F. Facchetti, O. Alebardi, H. Nakajima, A. Lanzavecchia, and M. Colonna Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon [see comments] Nat. Med. 5 1999 919 923 (Pubitemid 29372419)
20. + T cell responses to dominant and subdominant epitopes and protective immunity to Sendai virus infection by DNA vaccination J. Immunol. 160 1998 2425 2432 (Pubitemid 28119927)
21. D. Christensen, K.S. Korsholm, I. Rosenkrands, T. Lindenstrom, P. Andersen, and E.M. Agger Cationic liposomes as vaccine adjuvants Expert Rev. Vaccines 6 2007 785 796 (Pubitemid 47607853)
22. R.L. Coffman, A. Sher, and R.A. Seder Vaccine adjuvants: putting innate immunity to work Immunity 33 2010 492 503
23. K. Crozat, R. Guiton, V. Contreras, V. Feuillet, C.A. Dutertre, E. Ventre, T.P. Vu Manh, T. Baranek, A.K. Storset, J. Marvel, P. Boudinot, A. Hosmalin, I. Schwartz-Cornil, and M. Dalod The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8alpha+ dendritic cells J. Exp. Med. 207 2010 1283 1292
24. + T cell responses in humans Proc. Natl Acad. Sci. USA 101 2004 10697 10702 (Pubitemid 38955805)
25. I.A. de Bruijn, J. Nauta, L. Gerez, and A.M. Palache The virosomal influenza vaccine Invivac: Immunogenicity and tolerability compared to an adjuvanted influenza vaccine (Fluad) in elderly subjects Vaccine 24 2006 6629 6631 (Pubitemid 46107151)
26. W. De Haes, S. De Koker, C. Pollard, D. Atkinson, E. Vlieghe, J. Hoste, J. Rejman, S. De Smedt, J. Grooten, G. Vanham, and E. Van Gulck Polyelectrolyte capsules-containing HIV-1 p24 and poly I:C modulate dendritic cells to stimulate HIV-1-specific immune responses Mol. Ther. 18 2010 1408 1416
27. S. De Koker, B.G. De Geest, S.K. Singh, R. De Rycke, T. Naessens, Y. van Kooyk, J. Demeester, S.C. De Smedt, and J. Grooten Polyelectrolyte microcapsules as antigen delivery vehicles to dendritic cells: uptake, processing, and cross-presentation of encapsulated antigens Angew. Chem. Int. Ed. 48 2009 8485 8489
28. S. De Koker, B.N. Lambrecht, M.A. Willart, Y. van Kooyk, J. Grooten, C. Vervaet, J.P. Remon, and B.G. De Geest Designing polymeric particles for antigen delivery Chem. Soc. Rev. 40 2011 320 339
29. S.C. De Rosa, F.X. Lu, J. Yu, S.P. Perfetto, J. Falloon, S. Moser, T.G. Evans, R. Koup, C.J. Miller, and M. Roederer Vaccination in humans generates broad T cell cytokine responses J. Immunol. 173 2004 5372 5380 (Pubitemid 39392120)
30. J.M. den Haan, S.M. Lehar, and M.J. Bevan CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo J. Exp. Med. 192 2000 1685 1696
31. C.S.M. Diefenbach, S. Gnjatic, P. Sabbatini, C. Aghajanian, M.L. Hensley, D.R. Spriggs, A. Iasonos, H. Lee, B. Dupont, S. Pezzulli, A.A. Jungbluth, L.J. Old, and J. Dupont Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission Clin. Cancer Res. 14 2008 2740 2748
32. + T cell responses using a HCV core ISCOMATRIX vaccine: a phase I study in healthy volunteers Hum. Vaccine 5 2009 151 157
33. M.L. Dustin, and J.A. Cooper The immunological synapse and the actin cytoskeleton: molecular hardware for T cell signaling Nat. Immunol. 1 2000 23 29
34. J. Ehreth The value of vaccination: a global perspective Vaccine 21 2003 4105 4117 (Pubitemid 37130255)
35. L.D. Falo Jr., M. Kovacsovics-Bankowski, K. Thompson, and K.L. Rock Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity Nat. Med. 1 1995 649 653
36. T. Fifis, A. Gamvrellis, B. Crimeen-Irwin, G.A. Pietersz, J. Li, P.L. Mottram, I.F.C. McKenzie, and M. Plebanski Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors J. Immunol. 173 2004 3148 3154 (Pubitemid 39142021)
37. S. Fischer, E. Schlosser, M. Mueller, N. Csaba, H.P. Merkle, M. Groettrup, and B. Gander Concomitant delivery of a CTL-restricted peptide antigen and CpG ODN by PLGA microparticles induces cellular immune response J. Drug Target. 17 2009 652 661
38. + T cells in melanoma patients J. Immunother. 31 2008 781 791
39. J. Freund, J. Casals, and E.P. Hosmer Sensitization and antibody formation after injection of tubercle bacilli and paraffin oil Proc. Soc. Exp. Biol. Med. 37 1937 509 513
40. N. Garcon, P. Chomez, and M. Van Mechelen GlaxoSmithKline Adjuvant systems in vaccines: concepts, achievements and perspectives Expert Rev. Vaccines 6 2007 723 739 (Pubitemid 47607848)
41. N. Garcon, M. Wettendorff, and M.M. Van Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile Expert Opin. Biol. Ther. 11 2011 667 677
42. S.L. Giannini, E. Hanon, P. Moris, M. Van Mechelen, S. Morel, F. Dessy, M.A. Fourneau, B. Colau, J. Suzich, G. Losonksy, M.T. Martin, G. Dubin, and M.A. Wettendorff Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only Vaccine 24 2006 5937 5949 (Pubitemid 44080367)
43. R. Gluck, and I.C. Metcalfe New technology platforms in the development of vaccines for the future Vaccine 20 Suppl. 5 2002 B10 B16
44. B.S. Graham, M.J. McElrath, M.C. Keefer, K. Rybczyk, D. Berger, K.J. Weinhold, J. Ottinger, G. Ferarri, D.C. Montefiori, D. Stablein, C. Smith, R. Ginsberg, J. Eldridge, A. Duerr, P. Fast, and B.F. Haynes Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity Plos One 5 2010 e11995
45. P. Guermonprez, L. Saveanu, M. Kleijmeer, J. Davoust, E.P. Van, and S. Amigorena ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells Nature 425 2003 397 402 (Pubitemid 37187268)
46. K. Gurnani, J. Kennedy, S. Sad, G.D. Sprott, and L. Krishnan Phosphatidylserine receptor-mediated recognition of archaeosome adjuvant promotes endocytosis and MHC class I cross-presentation of the entrapped antigen by phagosome-to-cytosol transport and classical processing J. Immunol. 173 2004 566 578 (Pubitemid 38797385)
47. C.V. Harding, and R. Song Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecules J. Immunol. 153 1994 4925 4933 (Pubitemid 24356123)
48. L.A. Harshyne, S.C. Watkins, A. Gambotto, and S.M. Barratt-Boyes Dendritic cells acquire antigens from live cells for cross-presentation to CTL J. Immunol. 166 2001 3717 3723 (Pubitemid 32224894)
49. J.T. Harty, and M.J. Bevan Responses of CD8(+) T cells to intracellular bacteria Curr. Opin. Immunol. 11 1999 89 93 (Pubitemid 29082343)
50. W.R. Heath, G.T. Belz, G.M. Behrens, C.M. Smith, S.P. Forehan, I.A. Parish, G.M. Davey, N.S. Wilson, F.R. Carbone, and J.A. Villadangos Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens Immunol. Rev. 199 2004 9 26 (Pubitemid 38736761)
51. M. Houde, S. Bertholet, E. Gagnon, S. Brunet, G. Goyette, A. Laplante, M.F. Princiotta, P. Thibault, D. Sacks, and M. Desjardins Phagosomes are competent organelles for antigen cross-presentation Nature 425 2003 402 406 (Pubitemid 37187269)
52. S.W. Howland, and K.D. Wittrup Antigen release kinetics in the phagosome are critical to cross-presentation efficiency J. Immunol. 180 2008 1576 1583
53. C. Jacobs, P. Duewell, K. Heckelsmiller, J.W. Wei, F. Bauernfeind, J. Ellermeier, U. Kisser, C.A. Bauer, M. Dauer, A. Eigler, E. Maraskovsky, S. Endres, and M. Schnurr An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma Int. J. Cancer 128 2011 897 907
54. C.A. Janeway Jr., and K. Bottomly Signals and signs for lymphocyte responses Cell 76 1994 275 285 (Pubitemid 24046690)
55. P. Johansen, J.M.M. Gomez, and B. Gander Development of synthetic biodegradable microparticulate vaccines: a roller coaster story Expert Rev. Vaccines 6 2007 471 474 (Pubitemid 47304024)
56. P. Johansen, D. Mohanan, J.M. Martinez-Gomez, T.M. Kundig, and B. Gander Lympho-geographical concepts in vaccine delivery J. Controlled Release 148 2010 56 62
57. + (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens J. Exp. Med. 207 2010 1247 1260
58. + T cells by exogenous cell-associated antigens Immunity 17 2002 211 220 (Pubitemid 35245963)
59. Kakimi, K., Isobe, M., Uenaka, A., Wada, H., Sato, E., Doki, Y., Nakajima, J., Seto, Y., Yamatsuji, T., Naomoto, Y., Shiraishi, K., Takigawa, N., Kiura, K., Tsuji, K., Iwatsuki, K., Oka, M., Pan, L., Hoffman, E.W., Old, L.J., Nakayama, E., 2011. A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen. Int. J. Cancer doi: 10.1002/ijc.25955.
60. A.T. Kamath, M.P. Valenti, A.F. Rochat, E.M. Agger, K. Lingnau, G.A. Von, P. Andersen, P.H. Lambert, and C.A. Siegrist Protective anti-mycobacterial T cell responses through exquisite in vivo activation of vaccine-targeted dendritic cells Eur. J. Immunol. 38 2008 1247 1256
61. + T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival Int. J. Cancer 126 2010 909 918
62. S.P. Kasturi, I. Skountzou, R.A. Albrecht, D. Koutsonanos, T. Hua, H.I. Nakaya, R. Ravindran, S. Stewart, M. Alam, M. Kwissa, F. Villinger, N. Murthy, J. Steel, J. Jacob, R.J. Hogan, A. Garcia-Sastre, R. Compans, and B. Pulendran Programming the magnitude and persistence of antibody responses with innate immunity Nature 470 2011 543 547
63. M. Kovacsovics-Bankowski, K. Clark, B. Benacerraf, and K.L. Rock Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages Proc. Natl Acad. Sci. USA 90 1993 4942 4946 (Pubitemid 23182951)
64. M. Kovacsovics-Bankowski, and K.L. Rock A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules Science 267 1995 243 246
65. L. Krishnan, L. Deschatelets, F.C. Stark, K. Gurnani, and G.D. Sprott Archaeosome adjuvant overcomes tolerance to tumor-associated melanoma antigens inducing protective CD8 T cell responses Clin. Dev. Immunol. 2010 578432
66. L. Krishnan, S. Sad, G.B. Patel, and G.D. Sprott The potent adjuvant activity of archaeosomes correlates to the recruitment and activation of macrophages and dendritic cells in vivo J. Immunol. 166 2001 1885 1893 (Pubitemid 32114675)
67. + T cells of the effector (CD44highCD62Llow) and central (CD44highCD62Lhigh) phenotype by an archaeosome adjuvant independent of TLR2 J. Immunol. 178 2007 2396 2406 (Pubitemid 46233439)
68. L. Krishnan, and G.D. Sprott Archaeosome adjuvants: immunological capabilities and mechanism(s) of action Vaccine 26 2008 2043 2055
69. J. Kuball, K. de Boer, E. Wagner, M. Wattad, E. Antunes, R.D. Weeratna, A.P. Vicari, C. Lotz, S. van Dorp, S. Hol, P.D. Greenberg, W. Heit, H.L. Davis, and M. Theobald Pitfalls of vaccinations with WT1-, Proteinase3-and MUC1-derived peptides in combination with MontanideISA51 and CpG7909 Cancer Immunol. Immunother. 60 2011 161 171
70. A. Le Bon, and D.F. Tough Type I interferon as a stimulus for cross-priming Cytokine Growth Factor Rev. 19 2008 33 40
71. J.E. Ledgerwood, T.C. Pierson, S.A. Hubka, N. Desai, S. Rucker, I.J. Gordon, M.E. Enama, S. Nelson, M. Nason, W. Gu, N. Bundrant, R.A. Koup, R.T. Bailer, J.R. Mascola, G.J. Nabel, and B.S. Graham A west nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial J. Infect. Dis. 203 2011 1396 1404
72. G. Leroux-Roels Unmet needs in modern vaccinology: adjuvants to improve the immune response Vaccine 28 2010 C25 C36
73. G.B. Lipford, T. Sparwasser, M. Bauer, S. Zimmermann, E.S. Koch, K. Heeg, and H. Wagner Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines Eur. J. Immunol. 27 1997 3420 3426 (Pubitemid 28018040)
74. K. Liu, T. Iyoda, M. Saternus, Y. Kimura, K. Inaba, and R.M. Steinman Immune tolerance after delivery of dying cells to dendritic cells in situ J. Exp. Med. 196 2002 1091 1097 (Pubitemid 35231767)
75. M.A. Liu Gene-based vaccines: recent developments Curr. Opin. Mol. Ther. 12 2010 86 93
76. V. Manolova, A. Flace, M. Bauer, K. Schwarz, P. Saudan, and M.F. Bachmann Nanoparticles target distinct dendritic cell populations according to their size Eur. J. Immunol. 38 2008 1404 1413
77. M.L. Mbow, E. De Gregorio, N.M. Valiante, and R. Rappuoli New adjuvants for human vaccines Curr. Opin. Immunol. 22 2010 411 416
78. M. Menendez-Gonzalez, P. Perez-Pinera, M. Martinez-Rivera, A.L. Muniz, and J.A. Vega Immunotherapy for Alzheimer's disease: rational basis in ongoing clinical trials Curr. Pharm. Des. 17 2011 508 520
79. + T-cell tolerance by cross-presentation of self antigens Immunol. Rev. 165 1998 267 277 (Pubitemid 28524217)
80. J.J. Moon, H. Suh, A. Bershteyn, M.T. Stephan, H. Liu, B. Huang, M. Sohail, S. Luo, S.H. Um, H. Khant, J.T. Goodwin, J. Ramos, W. Chiu, and D.J. Irvine Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses Nat. Mater. 10 2011 243 251
81. N. Murthy, M.C. Xu, S. Schuck, J. Kunisawa, N. Shastri, and J.M.J. Frechet A macromolecular delivery vehicle for protein-based vaccines: acid-degradable protein-loaded microgels Proc. Natl Acad. Sci. USA 100 2003 4995 5000 (Pubitemid 36542647)
82. G. Mutwiri, V. Gerdts, S. den Hurk, G. Auray, N. Eng, S. Garlapati, L.A. Babiuk, and A. Potter Combination adjuvants: the next generation of adjuvants? Expert Rev. Vaccines 10 2011 95 107
83. T. Nicholaou, L.M. Ebert, I.D. Davis, G.A. McArthur, H. Jackson, N. Dimopoulos, B. Tan, E. Maraskovsky, L. Miloradovic, W. Hopkins, L. Pan, R. Venhaus, E.W. Hoffman, W. Chen, and J. Cebon Regulatory T-cell - Mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma Clin. Cancer Res. 15 2009 2166 2173
84. C.C. Norbury, B.J. Chambers, A.R. Prescott, H.G. Ljunggren, and C. Watts Constitutive macropinocytosis allows TAP-dependent major histocompatibility complex class I presentation of exogenous soluble antigen by bone marrow-derived dendritic cells Eur. J. Immunol. 27 1997 280 288 (Pubitemid 27046089)
85. C.C. Norbury, L.J. Hewlett, A.R. Prescott, N. Shastri, and C. Watts Class I MHC presentation of exogenous soluble antigen via macropinocytosis in bone marrow macrophages Immunity 3 1995 783 791 (Pubitemid 26091151)
86. P. Nordly, E.M. Agger, P. Andersen, H.M. Nielsen, and C. Foged Incorporation of the TLR4 agonist monophosphoryl lipid A into the bilayer of DDA/TDB liposomes: Physico-chemical characterization and induction of CD8(+) T-cell responses in vivo Pharm. Res. 28 2011 553 562
87. P. Nordly, H.B. Madsen, H.M. Nielsen, and C. Foged Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators Expert Opin. Drug Delivery 6 2009 657 672
88. P. Nordly, F. Rose, D. Christensen, H.M. Nielsen, P. Andersen, E.M. Agger, and C. Foged Immunity by formulation design: Induction of high CD8(+) T-cell responses by poly(I:C) incorporated into the CAF01 adjuvant via a double emulsion method J. Controlled Release 150 2011 307 317
89. D.T. O'Hagan, and E. De Gregorio The path to a successful vaccine adjuvant - 'The long and winding road' Drug Discovery Today 14 2009 541 551
90. D.T. O'Hagan, and N.M. Valiante Recent advances in the discovery and delivery of vaccine adjuvants Nat. Rev. Drug Discovery 2 2003 727 735 (Pubitemid 37361788)
91. C. Oussoren, and G. Storm Liposomes to target the lymphatics by subcutaneous administration Adv. Drug Deliv. Rev. 50 2001 143 156 (Pubitemid 32727280)
92. J. Panyam, W.Z. Zhou, S. Prabha, S.K. Sahoo, and V. Labhasetwar Rapid endo-lysosomal escape of poly(dl-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery FASEB J. 16 2002 1217 1226 (Pubitemid 34815409)
93. C.D. Partidos, P. Vohra, D.H. Jones, G. Farrar, and M.W. Steward Induction of cytotoxic T-cell responses following oral immunization with synthetic peptides encapsulated in PLG microparticles J. Controlled Release 62 1999 325 332 (Pubitemid 29476580)
94. S. Pichyangkul, U. Kum-Arb, K. Yongvanitchit, A. Limsalakpetch, A. Gettayacamin, D.E. Lanar, L.A. Ware, V.A. Stewart, D.G. Heppner, P. Mettens, J.D. Cohen, W.R. Ballou, and M.M. Fukuda Preclinical evaluation of the safety and immunogenicity of a vaccine consisting of Plasmodium falciparum liver-stage antigen 1 with adjuvant AS01B administered alone or concurrently with the RTS, S/AS01B vaccine in rhesus primates Infect. Immun. 76 2008 229 238
95. L.F. Poulin, M. Salio, E. Griessinger, F. njos-Afonso, L. Craciun, J.L. Chen, A.M. Keller, O. Joffre, S. Zelenay, E. Nye, M.A. Le, F. Faure, V. Donckier, D. Sancho, V. Cerundolo, D. Bonnet, and Reis e Sousa Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells J. Exp. Med. 207 2010 1261 1271
96. T.J. Powell, N. Palath, M.E. DeRome, J. Tang, A. Jacobs, and J.G. Boyd Synthetic nanoparticle vaccines produced by layer-by-layer assembly of artificial biofilms induce potent protective T-cell and antibody responses in vivo Vaccine 29 2011 558 569
97. S.D. Putney, and P.A. Burke Improving protein therapeutics with sustained-release formulations Nat. Biotechnol. 16 1998 153 157 (Pubitemid 128723585)
98. K. Radosevic, A. Rodriguez, R. Mintardjo, D. Tax, K.L.V. Bengtsson, C. Thompson, M. Zambon, G.J. Weverling, F. UytdeHaag, and J. Goudsmit Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants Vaccine 26 2008 3640 3646
99. R. Rappuoli Bridging the knowledge gaps in vaccine design Nat. Biotechnol. 25 2007 1361 1366 (Pubitemid 350233122)
100. S.T. Reddy, D.V. Van, E. Simeoni, V. Angeli, G.J. Randolph, C.P. O'Neil, L.K. Lee, M.A. Swartz, and J.A. Hubbell Exploiting lymphatic transport and complement activation in nanoparticle vaccines Nat. Biotechnol. 25 2007 1159 1164 (Pubitemid 47538111)
101. C. Reis e Sousa, and R.N. Germain Major histocompatibility complex class I presentation of peptides derived from soluble exogenous antigen by a subset of cells engaged in phagocytosis J. Exp. Med. 182 1995 841 851
102. C. Reis e Sousa, P.D. Stahl, and J.M. Austyn Phagocytosis of antigens by Langerhans cells in vitro J. Exp. Med. 178 1993 509 519 (Pubitemid 23218199)
103. K.L. Rock, and L. Shen Cross-presentation: underlying mechanisms and role in immune surveillance Immunol. Rev. 207 2005 166 183 (Pubitemid 41415016)
104. P.C. Rodriguez, G. Rodriguez, G. Gonzalez, and A. Lage Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy MEDICC Rev. 12 2010 17 23
105. J.T. Schiller, X. Castellsague, L.L. Villa, and A. Hildesheim An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results Vaccine 26 Suppl. 10 2008 K53 K61
106. A. Sexton, P.G. Whitney, S.F. Chong, A.N. Zelikin, A.P.R. Johnston, R. De Rose, A.G. Brooks, F. Caruso, and S.J. Kent A protective vaccine delivery system for in vivo T cell stimulation using nanoengineered polymer hydrogel capsules ACS Nano 3 2009 3391 3400
107. N.A. Sheikh, G.S. Attard, R.N. Van, P. Rajananthanan, K. Hariharan, Y.W. Yang, and W.J. Morrow Differential requirements for CTL generation by novel immunostimulants: APC tropism, use of the TAP-independent processing pathway, and dependency on CD80/CD86 costimulation Vaccine 21 2003 3775 3788 (Pubitemid 37338205)
108. H. Shen, A.L. Ackerman, V. Cody, A. Giodini, E.R. Hinson, P. Cresswell, R.L. Edelson, W.M. Saltzman, and D.J. Hanlon Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles Immunology 117 2006 78 88
109. Z. Shen, G. Reznikoff, G. Dranoff, and K.L. Rock Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules J. Immunol. 158 1997 2723 2730 (Pubitemid 127470530)
110. S. Shresta, C.T. Pham, D.A. Thomas, T.A. Graubert, and T.J. Ley How do cytotoxic lymphocytes kill their targets? Curr. Opin. Immunol. 10 1998 581 587 (Pubitemid 28479192)
111. A. Sjolander, D. Drane, E. Maraskovsky, J.P. Scheerlinck, A. Suhrbier, J. Tennent, and M. Pearse Immune responses to ISCOM formulations in animal and primate models Vaccine 19 2001 2661 2665 (Pubitemid 32234286)
112. + T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909 J. Clin. Invest. 115 2005 739 746 (Pubitemid 40322250)
113. P. Srivastava Roles of heat-shock proteins in innate and adaptive immunity Nat. Rev. Immunol. 2 2002 185 194 (Pubitemid 37328765)
114. R.M. Steinman, L. Bonifaz, S. Fujii, K. Liu, D. Bonnyay, S. Yamazaki, M. Pack, D. Hawiger, T. Iyoda, K. Inaba, and M.C. Nussenzweig The innate functions of dendritic cells in peripheral lymphoid tissues Adv. Exp. Med. Biol. 560 2005 83 97
115. S. Stenger, D.A. Hanson, R. Teitelbaum, P. Dewan, K.R. Niazi, C.J. Froelich, T. Ganz, S. Thoma-Uszynski, A. Melian, C. Bogdan, S.A. Porcelli, B.R. Bloom, A.M. Krensky, and R.L. Modlin An antimicrobial activity of cytolytic T cells mediated by granulysin Science 282 1998 121 125 (Pubitemid 28471143)
116. S. Stenger, R.J. Mazzaccaro, K. Uyemura, S. Cho, P.F. Barnes, J.P. Rosat, A. Sette, M.B. Brenner, S.A. Porcelli, B.R. Bloom, and R.L. Modlin Differential effects of cytolytic T cell subsets on intracellular infection Science 276 1997 1684 1687 (Pubitemid 27421972)
117. H.X. Sun, Y. Xie, and Y.P. Ye ISCOMs and ISCOMATRIX(TM) Vaccine 27 2009 4388 4401
118. M.A. Swartz The physiology of the lymphatic system Adv. Drug Deliv. Rev. 50 2001 3 20 (Pubitemid 32727274)
119. H. Tamber, P. Johansen, H.P. Merkle, and B. Gander Formulation aspects of biodegradable polymeric microspheres for antigen delivery Adv. Drug Deliv. Rev. 57 2005 357 376 (Pubitemid 39555502)
120. K.K. Tran, and H. Shen The role of phagosomal pH on the size-dependent efficiency of cross-presentation by dendritic cells Biomaterials 30 2009 1356 1362
121. D. Valmori, N.E. Souleimanian, V. Tosello, N. Bhardwaj, S. Adams, D. O'Neill, A. Pavlick, J.B. Escalon, C.M. Cruz, A. Angiulli, F. Angiulli, G. Mears, S.M. Vogel, L. Pan, A.A. Jungbluth, E.W. Hoffmann, R. Venhaus, G. Ritter, L.J. Old, and M. Ayyoub Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming Proc. Natl Acad. Sci. USA 104 2007 8947 8952 (Pubitemid 47175417)
122. M. van de Weert, W.E. Hennink, and W. Jiskoot Protein instability in poly(lactic-co-glycolic acid) microparticles Pharm. Res. 17 2000 1159 1167
123. P. Vandepapeliere, Y. Horsmans, P. Moris, M. Van Mechelen, M. Janssens, M. Koutsoukos, P. Van Belle, F. Clement, E. Hanon, M. Wettendorff, N. Garcon, and G. Leroux-Roels Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers Vaccine 26 2008 1375 1386
124. J.A. Villadangos, and P. Schnorrer Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo Nat. Rev. Immunol. 7 2007 543 555 (Pubitemid 46987783)
125. J. Wolfers, A. Lozier, G. Raposo, A. Regnault, C. Thery, C. Masurier, C. Flament, S. Pouzieux, F. Faure, T. Tursz, E. Angevin, S. Amigorena, and L. Zitvogel Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming Nat. Med. 7 2001 297 303 (Pubitemid 32224344)
126. Y. Wu, R.D. Ellis, D. Shaffer, E. Fontes, E.M. Malkin, S. Mahanty, M.P. Fay, D. Narum, K. Rausch, A.P. Miles, J. Aebig, A. Orcutt, O. Muratova, G. Song, L. Lambert, D. Zhu, K. Miura, C. Long, A. Saul, L.H. Miller, and A.P. Durbin Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51 Plos One 3 2008 e2636
127. J.W. Yewdell, and S.M.M. Haeryfar Understanding presentation of viral antigens to CD8(+) T cells in vivo: the key to rational vaccine design Annu. Rev. Immunol. 23 2005 651 682 (Pubitemid 40563182)
128. + T cell responses to infectious agents, tumors, transplants, and vaccines Adv. Immunol. 73 1999 1 77 (Pubitemid 29300428)
129. J.W. Yewdell, E. Reits, and J. Neefjes Making sense of mass destruction: quantitating MHC class I antigen presentation Nat. Rev. Immunol. 3 2003 952 961 (Pubitemid 37521537)
130. K. Zaks, M. Jordan, A. Guth, K. Sellins, R. Kedl, A. Izzo, C. Bosio, and S. Dow Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes J. Immunol. 176 2006 7335 7345 (Pubitemid 43849034)
131. C.C. Zarozinski, E.F. Fynan, L.K. Selin, H.L. Robinson, and R.M. Welsh Protective CTL-dependent immunity and enhanced immunopathology in mice immunized by particle bombardment with DNA encoding an internal virion protein J. Immunol. 154 1995 4010 4017
132. F. Zepp Principles of vaccine design-Lessons from nature Vaccine 28 Suppl. 3 2010 C14 C24
133. Q. Zhu, C. Egelston, S. Gagnon, Y.J. Sui, I.M. Belyakov, D.M. Klinman, and J.A. Berzofsky Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice J. Clin. Invest. 120 2010 607 616
134. L. Zitvogel, A. Regnault, A. Lozier, J. Wolfers, C. Flament, D. Tenza, P. Ricciardi-Castagnoli, G. Raposo, and S. Amigorena Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes Nat. Med. 4 1998 594 600 (Pubitemid 28237359)